Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.
de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK. de la Puente P, et al. Among authors: vij r. Haematologica. 2016 Jul;101(7):e307-11. doi: 10.3324/haematol.2016.142190. Epub 2016 Apr 14. Haematologica. 2016. PMID: 27081175 Free PMC article. No abstract available.
Carfilzomib in multiple myeloma.
Vij R. Vij R. Clin Adv Hematol Oncol. 2012 Sep;10(9):591-3. Clin Adv Hematol Oncol. 2012. PMID: 23073124 No abstract available.
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK. Azab F, et al. Among authors: vij r. Br J Haematol. 2014 Apr;165(1):89-101. doi: 10.1111/bjh.12734. Epub 2014 Jan 9. Br J Haematol. 2014. PMID: 24405121 Free article.
Personalization of cancer treatment using predictive simulation.
Doudican NA, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, Abbasi T, Vali S, Vij R, Fiala M, King J, Perle M, Mazumder A. Doudican NA, et al. Among authors: vij r. J Transl Med. 2015 Feb 1;13:43. doi: 10.1186/s12967-015-0399-y. J Transl Med. 2015. PMID: 25638213 Free PMC article.
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK. de la Puente P, et al. Among authors: vij r. J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28. J Control Release. 2018. PMID: 29196043 Free PMC article.
A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH. White BS, et al. Among authors: vij r. Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y. Blood Cancer J. 2018. PMID: 29563506 Free PMC article.
452 results